The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I NRG-LU004
Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
NRG Oncology
Lin, Steven H.
(713) 563-8490
Phase I/II 10200
Combination Pinometostat and 5-Azacitidine for the Treatment of Patients with Relapsed / Refractory Acute Myeloid Leukemia, or Newly Diagnosed Patients who are Ineligible for or Unwilling to Undergo Intensive Therapy, who Harbor an 11q23 Rearrangement
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Stein, Eytan M.
(212) 639-3314
Phase I/II 10212
A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement
Ohio State University Comprehensive Cancer Center LAO
Blachly, James Stewart
(614) 685-5667
Phase I/II EAA172
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or Without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status
ECOG-ACRIN Cancer Research Group
Thompson, Michael A.
(414) 219-4763
Phase II 10181
A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer
Duke University – Duke Cancer Institute LAO
Strickler, John Howard
(919) 681-6006
Phase II ANBL17P1
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma
Children’s Oncology Group
Federico, Sara Michele
(901) 595-7942
Phase II EAQ171CD
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0”
ECOG-ACRIN Cancer Research Group
Park, Elyse
(617) 724-6836
Phase II S1900A
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
SWOG
Riess, Jonathan W.
(916) 734-3772
Phase II/III A041701
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Alliance for Clinical Trials in Oncology
Uy, Geoffrey L.
(314) 747-8439
Phase Other AEWS18B3-Q
Identifying Inherited Germline Variation Associated with Ewing Sarcoma Risk
Children’s Oncology Group
Machiela, Mitchell
(240) 760-6518
Phase Other AHOD18B2-Q
Identifying Treatment Response Predictors in Pediatric Hodgkin Lymphoma; A Validation Set for AHOD12B2
Children’s Oncology Group
Horton, Terzah M.
(832) 824-4269
Phase Other AREN18B5-Q
Genomic Analysis of Bilateral Wilms Tumor
Children’s Oncology Group
Murphy, Andrew Jackson
(901) 930-5205
Phase Other S1800NMIO
A LUNG-MAP Version Control Protocol for Non-Matched Immunotherapy Sub-Studies
SWOG
Papadimitrakopoulou, Vassiliki A.
(713) 792-6363
Phase Other S1900BDSS
A Lung-MAP Version Control Protocol for Biomarker-Driven Sub-Studies
SWOG
Papadimitrakopoulou, Vassiliki A.
(713) 792-6363
Phase Other URCC-18004CD
Understanding the Impact of Drug Shortages on Oncology Care Delivery
University of Rochester NCORP Research Base
Hill, Elaine
(585) 275-0165
